Since GPCRs are highly expressed in ovarian cancer [25,26,27], we explored the expression and functional role of RGS2 in HGSOC, analyzed its associations with clinicopathological characteristics, and determined the prognostic impact of RGS2 expression both in a large independent cohort of more than 500 patients on the protein level by immunohistochemistry and in silico on the mRNA level. The gene discussed is RGS2; the disease is ovarian cancer.